KOHLI-VENTURES
10.6.2019 10:02:18 CEST | Business Wire | Press release
At London Tech Week: Tej Kohli, the London-based tech entrepreneur, has invested another $100m into Rewired, a robotics-focused venture studio with a humanitarian bent. Rewired is pioneering investment into artificial intelligence and machine learning ventures that will power the new economy, transform businesses, revolutionise global healthcare and even improve and extend human life.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190610005161/en/
Some of the companies already backed by Rewired include:
- Open Bionics: is developing the next generation of prosthetics, which for the first time enable patients to feel their surrounding environment through their prosthesis.
- Aromyx: is developing technologies that for the first time enable scientifically reproducible measurement and digitisation of taste and scent. Applications include the detection and capture of new data modalities for machine learning.
- Seldon: has developed the world’s first open source machine learning platform to enable data scientists, developers and large organisations to share data, thus harnessing the network effect for machine learning and enabling machines to learn faster, bigger and better.
Current thinking suggests that the global AI market will be worth anything from $3.9 trillion by 2022 (Gartner) to $15.7 trillion by 2030 (PWC) – but Tej Kohli believes that the true value could be much greater.
Kohli commented:
“Conventional wisdom is too cautious. I predict that the global AI sector will be worth $150 trillion by 2025. My forecast is based on a five-part analysis:
- The Internet today is worth $50 trillion. You can take that and extrapolate it to at least three or four times as many applications as the Internet to get $150 trillion. I don’t see how it can be any less because AI has so many different industries and applications;
- Everything that is currently on the Internet can also be manifested through AI in smarter and better and more effective ways. These Internet-linked applications alone are worth hundreds of billions – and AI can be similarly applied across hundreds of other industries;
- The rapid pace of growth of AI in China, with Shenzen now a global hub of AI excellence that will surpass the ever more regulated Silicon Valley in the medium term;
- The global growth in 5G coverage plus ubiquitous smartphone usage removing technological barriers to embracing the AI revolution in a true Internet of Things;
- That we are now at a tipping point, after which AI and machine learning will grow exponentially to underpin and benefit every single aspect of human life.
“I am not saying that $150 trillion is based on a complete adoption of AI across everything. I believe $150 trillion is where you get to when keeping our basic human norms and values intact. It is using AI to make our lives more efficient without radically changing our lives to the full extent that AI is capable of. I estimate this value to be three to four times the Internet.
“And I believe that AI will enable humanity to take unprecedented leaps forward in solving the most pressing human problems across poverty, geopolitics and unequal access to healthcare, by virtue of its ability to make businesses and organisations far more efficient. There is scope for huge commercial gain coupled with unprecedented opportunities for human progress.”
About Tej Kohli
Tej Kohli is a London-based technology and real estate entrepreneur, businessman and philanthropist who now focuses on visionary ventures and investments that have the potential to transform lives and change the world. Through his investment vehicle Kohli Ventures, Mr Kohli targets high-impact investments into AI, robotics, biotech, genomics and Fintech that help to solve the world’s most pressing challenges and create a better tomorrow.
Mr Kohli also has a well-publicized mission to cure corneal blindness worldwide by 2030 through the philanthropic Tej Kohli Foundation that provides direct funding for the Tej Kohli Cornea Institute, a preeminent global institute for solving corneal blindness worldwide.
Mr Kohli is a Distinguished Alumnus of the Indian Institute of Technology in Kanpur (IITK) where he completed a degree in Electrical Engineering. He first rose to success building innovative white label technology and e-commerce solutions for companies during the dot com boom.
About Rewired
Rewired is a robotics-focused venture studio specializing in applied science and technologies. Rewired launched in 2017 with an initial $100 million fund for technologies that will enable robots to interact properly with real-world environments. In backing the development of robots’ sensory capabilities and understanding of the world around them, Rewired seeks to play a major part in enabling the safe and efficient integration of machine learning into everyday life.
For more information about Rewired see https://youtu.be/6yc5EcBIU5U
ENDS
View source version on businesswire.com: https://www.businesswire.com/news/home/20190610005161/en/
Contact:
For an interview with Tej Kohli please contact: Mike Macfarlane mike@kohliventures.com +447764 225 924
Helen Tarbet / Kim van Beeck / Hannah Ratcliff (Buchanan) kohliventures@buchanan.uk.com +4420 7466 5000
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press release
- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine p
Andersen Consulting udvider med TalentSmartEQ for at fremme lederskab og virksomhedstransformation9.10.2026 18:48:00 CEST | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for humankapital gennem en samarbejdsaftale med TalentSmartEQ, en San Diego-baseret virksomhed, der har fokus på at skabe praktiske, engagerende og handlingsorienterede læringsoplevelser med udgangspunkt i emotionel intelligens (EQ) og lederudvikling. I mere end to årtier har TalentSmartEQ arbejdet sammen med organisationer verden over med henblik på at udvikle ledelseskompetencer ved hjælp af emotionel intelligens og dermed styrke medarbejderengagement, teamwork og de samlede resultater. Virksomheden kombinerer forskningsbaserede metoder med praktiske læringsforløb, vurderinger, coaching og skræddersyede programmer, der skal omsætte opbygningen af emotionel intelligens til vedvarende ændringer i adfærden på arbejdspladsen. Som førende aktør i branchen samarbejder TalentSmartEQ med organisationer lige fra Fortune 500-virksomheder til offentlige myndigheder og privatejede virksomheder. "Organisationer stiller stadig større krav til dere
Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 16:00:00 CEST | Press release
Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation and reinforcing the security architecture behind each financial guarantee Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Sta
Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 15:17:00 CEST | Press release
We think Gartner recognizes Tecnotree's open, governed approach to agentic AI as operators make AI the engine of their revenue operations Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magi
Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 15:15:00 CEST | Press release
Data Presented at Annual Meeting of European Association for Cardio-Thoracic Surgery (EACTS), Along with 6 Perceval Plus E-PostersEACTS Also Marks Commercial Launch of TriMemo and Memo 4D Curve, Innovative Repair Devices for Tricuspid and Mitral Valves Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
